Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent protected DETERx™ formulation platform.

The Company currently has two product candidates in clinical development. COL-003 and COL-172 have both received Fast Track designation by the FDA due to their potential to address a major public health issue.